Tag Archives: Larry Biegelsen

Wells Fargo Believes NovoCure Ltd (NASDAQ: NVCR) Still Has Room to Grow

In a report released today, Larry Biegelsen from Wells Fargo maintained a Buy rating on NovoCure Ltd (NASDAQ: NVCR). The company’s shares opened today at $48.90, close to its 52-week high of $49.25. According to TipRanks.com, Biegelsen is a 5-star

Wells Fargo Believes Johnson & Johnson (NYSE: JNJ) Won’t Stop Here

In a report released today, Larry Biegelsen from Wells Fargo reiterated a Buy rating on Johnson & Johnson (NYSE: JNJ), with a price target of $160. The company’s shares opened today at $144.99, close to its 52-week high of $146.15.

Analysts Conflicted on These Healthcare Names: NovoCure Ltd (NASDAQ: NVCR) and Bioverativ Inc (NASDAQ: BIVV)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on NovoCure Ltd (NASDAQ: NVCR) and Bioverativ Inc (NASDAQ: BIVV). NovoCure Ltd (NASDAQ: NVCR) Wells Fargo analyst Larry Biegelsen upgraded NovoCure Ltd (NASDAQ: NVCR) to Buy

Cooper Co. Receives a Hold from Wells Fargo

Wells Fargo analyst Larry Biegelsen reiterated a Hold rating on Cooper Co. (NYSE: COO) on September 9. The company’s shares closed last Friday at $184.83, close to its 52-week high of $189.98. According to TipRanks.com, Biegelsen is a 5-star analyst

K2M Group Holdings Receives a Buy from Wells Fargo

Wells Fargo analyst Larry Biegelsen reiterated a Buy rating on K2M Group Holdings (NASDAQ: KTWO) on September 9. The company’s shares closed last Friday at $16.43. According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of 16.7%

Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (NYSE: EW), Hill-Rom (NYSE: HRC) and Diplomat Pharmacy (NYSE: DPLO)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Edwards Lifesciences (NYSE: EW), Hill-Rom (NYSE: HRC) and Diplomat Pharmacy (NYSE: DPLO). Edwards Lifesciences (NYSE: EW) In a report issued on September 9,